Delivery Order SPE2DB22D9239-SPE2DB24FDM09

Award Date 8/28/24
Potential Completion Date 9/19/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $24,623.52, is for the delivery of the oncology drug Kadcyla 160 mg vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and covers the delivery of Kadcyla 100 mg vials, a specialty oncology medication, with a completion date of August 15, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $51,195.60 and has a completion date of February 15, 2024. The contract is for the supply of Kadcyla 100 mg vials, a specialized oncology medication, to support the recurring medical supply needs of military health facilities worldwide. This order is part...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, with a period of performance through August 28, 2024. DMS Pharmaceutical Group holds a large single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999, which allows the...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through July 19, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of 160 mg vials of the oncology drug Kadcyla. The contract is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,119.56 contract is for the delivery of Kadcyla 100mg vials, a specialty oncology medication. The order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA to provide a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,798.90, is for the delivery of 100 mg vials of the drug Kadcyla. The delivery order is part of a larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, that allows the agency to issue orders for a comprehensive range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, a prescription oncology drug, with a completion date of August 13, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 160 mg vials of the oncology medication Kadcyla, with a total ceiling value of $12,247.72 and a period of performance through June 14, 2022. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDM09
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and an ultimate completion date of September 19, 2024. It is part of the larger SPE2DB indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which runs through December 31, 2025.

Under this delivery order, DMS Pharmaceutical Group will provide 100 mg vials of the oncology drug Kadcyla to support the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation. As a prime vendor for the DLA's Medical Supply Chain division, DMS Pharmaceutical Group supplies a wide range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and Department of Veterans Affairs (VA), including common medications as well as specialized drugs and biologics.

Generated 11/27/24, 9:10 AM